# US 2016/0256476 A1 · Novel parasite therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256476 A1
- Document ID: US20160256476A1
- Status: Published application
- Kind: A1
- Application number: 15/154,419
- Filed: 2016-05-13
- Published: 2016-09-08
- Earliest claimed: 2009-10-22
- Inventors: Thomas Julius Borody
- Web page: https://patentgrep.com/patent/US20160256476A1

## CPC

- A61K 31/65: Tetracyclines
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/42: Oxazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/426: 1,3-Thiazoles
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 17/00: Drugs for dermatological disorders
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/04: Amoebicides
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate. There is also disclosed herein a method for treating extracellular parasitic infections in a vertebrate in need of said treatment, wherein said treatment comprises administering to said vertebrate a therapeutically effective amount of (i) a composition comprising a quinolone or fluoroquinolone together with a pharmaceutically acceptable carrier or (ii) a composition of the invention or (iii) a combination of at least one quinolone or fluoroquinolone optionally together with at least one tetracycline, iodoquinol, an azole or imidazole; or (iv) a combination of at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.

## Claims

### Claim 1

A composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations:
at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or
at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.

### Claim 2 (depends on 1)

The composition according to claim 1 wherein the quinolone or fluoroquinolone is one or more compounds selected from the group consisting of cinoxacin, flumequine, oxolinic acid, piromidic acid, ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, nadifloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, grepafloxacin, levofloxacin, pazufloxacin mesilate, sparfloxacin, temafloxacin, tosufloxacin, clinafloxacin, gemifloxacin, moxifloxacin, gatifloxacin, sitafloxacin, trovafloxacin, ecinofloxacin, and prulifloxacin.

### Claim 3 (depends on 1, 2)

The composition according to claim 1 or 2 wherein the tetracycline is tetracycline, chlortetracycline, oxytetracycline, demeclocycline, doxycycline, lymecycline, meclocycline, minocycline, methacycline, rolitetracycline and penimepicycline.

### Claim 4 (depends on 1, 2, 3)

The composition according to claim 1, 2 or 3 wherein the azole or imidazole is selected from ketoconazole, fluconazole, miconazole, clotrimazole, tioconazole, sulconazole, econazole, itraconazole and mixtures thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The composition according to any one of claims 1 to 4 further comprising an additional anti-parasitic drug.

### Claim 6 (depends on 5)

The composition according to claim 5 wherein the anti-parasitic drug is selected from emetine, quinacrine, satranidazole, flunidazole, ronidazole and mixtures thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6 wherein the thiazolidone is selected from the group consisting of nitazoxanide, denitrozoxanide, tizoxanide and mixtures thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1 to 7 wherein the nitroimidazole is selected from metronidazole, etronidazole, secnidazole, tinidazole, ornidazole, furazolidone and mixtures thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The composition according to any one of claims 1 to 8 including combinations of three or four different agents.

### Claim 10 (depends on 1)

The composition of claim 1 including the combination norfloxacin and ketoconazole.

### Claim 11 (depends on 1)

The composition of claim 1 including the combination nitazoxanide, furzolidone and secnidazole.

### Claim 12 (depends on 1)

The composition of claim 1 including the combination iodoquinol, furazolidone and nitazoxanide.

### Claim 13 (depends on 1)

The composition of claim 1 including the combination diloxanide furoate, doxycycline and metronidazole.

### Claim 14 (depends on 1)

The composition of claim 1 including the combination secnidazole, diloxanide furoate and cotrimoxazole.

### Claim 15 (depends on 1)

The composition of claim 1 including the combination metronidazole, nitazoxanide and furazolidone.

### Claim 16 (depends on 1)

The composition of claim 1 including the combination cotrimoxazole, diloxanide furoate, secnidazole and doxycycline.

### Claim 17 (depends on 1)

The composition of claim 1 including the combination nitazoxanide, furazolidone, secnidazole and doxycycline.

### Claim 18 (depends on 1)

The composition according to claim 1 wherein the composition includes two agents selected from iodoquinol and doxycycline, nitazoxanide and doxycycline, nitazoxanide and secnidazole, furazolidone and secnidazole, furazolidone and nitazoxanide, doxycycline and secnidazole and doxycycline and furazolidone and mixtures thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for treating extracellular parasitic infections in a vertebrate in need of said treatment, wherein said treatment comprises administering to said vertebrate a therapeutically effective amount of (i) a composition comprising a quinolone or fluoroquinolone together with a pharmaceutically acceptable carrier or (ii) a composition of any one of claims 1 to 18, or (iii) a combination of at least one quinolone or fluoroquinolone optionally together with at least one tetracycline, iodoquinol, an azole or imidazole; or (iv) a combination of at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.

### Claim 20 (depends on 19)

The method of claim 19 wherein the extracellular parasite is Blastocystis hominis, Dientamoeba fragilis or both.

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20 including administering a dosage of at least one milligram to five grams per day.

### Claim 22 (depends on 19, 20)

The method of any one of claims 19 to 20 wherein the quinolone or fluoroquinolone is norfloxacin.

### Claim 23

Use of at least one quinolone or fluoroquinolone optionally together with at least one tetracycline, iodoquinol, an azole or imidazole; or
at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate for the manufacture of a medicament for treating extracellular parasitic infections.
